- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Bioatla Inc (BCAB)
The Bioatla share price today is 3.355, view NASDAQ BCAB stock exchange data. Track the latest Bioatla share price with real-time updates on BCAB stock performance including market cap, day range, 52-week range and dividend yield. Access BCAB charts, earnings dates and analyst estimates to support your investment decisions.
3.355
-0.565(-14.41%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.260
4.075
52 wk Range
3.260
71.500
Trading near 52-week Low
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2604.075
52 wk Range
3.26071.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BCAB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
10.000
Upside
+198.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 8K Bioatla Inc For: 9 February
- Investing.com
- Form 8K Bioatla Inc For: 2 March
- Investing.com
- BioAtla explores sale as it cuts 70% of workforce
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.000
(+198.06% Upside)
Bioatla Inc SWOT Analysis
CAB Platform Promise | BioAtla's innovative conditionally active biologics aim to revolutionize cancer treatment, enhancing potency while reducing side effects |
Financial Fortitude | Strong liquidity with $32M cash, extended runway to 2026, and strategic cost-cutting measures position BioAtla for continued clinical advancement |
Pipeline Progress | Explore BioAtla's promising candidates, including BA3182 and Mec-V, showing encouraging anti-tumor activity in ongoing clinical trials |
Market Outlook | Analysts set price targets ranging from $1 to $5, reflecting cautious optimism amid BioAtla's pivotal year of clinical developments and partnership pursuits |
Bioatla Inc Earnings Call Summary for Q3/2025
- Bioatla reported Q3 2025 EPS of -$0.27, meeting forecasts, but stock fell 4.09% to $0.67 amid investor concerns over increased net losses of $15.8M and low cash reserves of $8.3M.
- Despite cost management efforts reducing R&D and G&A expenses, the company's net loss increased from $10.6M in Q3 2024, raising questions about financial sustainability.
- Bioatla achieved FDA alignment for a phase 3 trial in OPSCC, with CEO Jay Short announcing plans to begin enrollment early next year and key clinical readouts expected in H1 2026.
- Management plans to finalize a strategic transaction by year-end, focusing on prioritized programs while addressing the company's precarious cash position.
Last Updated: 14-11-2025, 03:54 am
Read Full TranscriptEarnings
Latest Release
13-05-2026
EPS / Forecast
-- / -0.20
Revenue / Forecast
-- / --
Compare BCAB to Peers and Sector
Metrics to compare | BCAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.1x | −1.5x | −0.5x | |
PEG Ratio | 0.00 | −0.12 | 0.00 | |
Price/Book | −0.2x | 2.8x | 2.6x | |
Price / LTM Sales | 3.2x | 12.5x | 3.2x | |
Upside (Analyst Target) | - | 56.6% | 55.3% | |
Fair Value Upside | Unlock | 11.3% | 9.7% | Unlock |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Bioatla (BCAB) Share Price Today?
The Bioatla share price today is 3.355.
What is the current Bioatla (BCAB) share price and day range?
As of 19-05-2026, the Bioatla share price is 3.355, with a previous close of 3.920. The share price has ranged from 3.260 to 4.075 today, while the 52-week range spans from 3.260 to 71.500.
What Is the Bioatla Market Cap?
As of today, Bioatla market cap is 5.560M.
What Is the Bioatla (BCAB) Share Price Target?
The average 12-month share price target for Bioatla is 10.000, with a high estimate of 10 and a low estimate of 10. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +198.06% Upside potential.
What Is Bioatla's Earnings Per Share (TTM)?
The Bioatla EPS (TTM) is -40.149.
When Is the Next Bioatla Earnings Date?
Bioatla will release its next earnings report on 13-05-2026.
From a Technical Analysis Perspective, Is BCAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Bioatla Trade On?
Bioatla is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Bioatla?
The stock symbol for Bioatla is "BCAB."
How Many Times Has Bioatla Stock Split?
Bioatla has split 1 times.
How Many Employees Does Bioatla Have?
Bioatla has 41 employees.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.